Assess whether scientific advice should be sought before the next trial

Situation

Phase-3 protocol with endpoint-sensitivity issues arrived with a site-change that invalidates stability claims for labeling negotiator. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on scientific advice should be in an RWE group proposing a post-marketing study instead of a new RCT.

Decision

Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after a site-change that invalidates stability claims.

Hypotheses to test

• Authorize Proceed under protocol now; phase-3 protocol with endpoint-sensitivity issues already has the discriminator after a site-change that invalidates stability claims.
• Keep Pause the pathway in force until phase-3 protocol with endpoint-sensitivity issues is completed after a site-change that invalidates stability claims for labeling negotiator.
• Treat phase-3 protocol with endpoint-sensitivity issues as Escalate safety review because both readings appear after a site-change that invalidates stability claims.
• Refuse a Pharma & Life Sciences close: labeling negotiator does not have the page scientific advice should be turns on in phase-3 protocol with endpoint-sensitivity issues.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be.
• Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim labeling negotiator would keep.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read phase-3 protocol with endpoint-sensitivity issues against a site-change that invalidates stability claims and write the one fact that would move scientific advice should be for labeling negotiator.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (phase-3 protocol with endpoint-sensitivity issues after a site-change that invalidates stability claims). The follow-on Clinical and Evidence Strategy action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.